Camurus receives positive CHMP opinion for Buvidal 160mg monthly dose for the treatment of opioid dependence ...Middle East

LUND, Sweden, March 26, 2021 /PRNewswire/ -- Camurus today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency's (EMA) has issued a positive opinion recommending marketing authorization for a new, 160mg, monthly dose of Buvidal®...

Hence then, the article about camurus receives positive chmp opinion for buvidal 160mg monthly dose for the treatment of opioid dependence was published today ( Friday 26/03/2021 - 05:00 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Camurus receives positive CHMP opinion for Buvidal 160mg monthly dose for the treatment of opioid dependence )

Also on site :

• Armed police close Lewes Road
• Intrigue, Power Plays and Rivalries: Inside the Rise of Mojtaba Khamenei
• Fire erupts at Dubai airport following drone attack